Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review
Authors:
- 22 July 2008
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 102 (4) , 426-431
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Effects of testosterone on erectile function: implications for the therapy of erectile dysfunctionBJU International, 2007
- A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis®) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Acetyl-l-carnitine plus propionyl-l-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomyUrology, 2005
- Phosphodiesterase type 5 inhibitors for erectile dysfunctionBJU International, 2005
- Cancer incidence and mortality in Europe, 2004Annals of Oncology, 2005
- TADALAFIL IN THE TREATMENT OF ERECTILE DYSFUNCTION FOLLOWING BILATERAL NERVE SPARING RADICAL RETROPUBIC PROSTATECTOMY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIALJournal of Urology, 2004
- Sildenafil Preserves Intracorporeal Smooth Muscle After Radical Retropubic ProstatectomyJournal of Urology, 2004
- Safety and Efficacy of Vardenafil for the Treatment of Men With Erectile Dysfunction After Radical Retropubic ProstatectomyJournal of Urology, 2003
- Urinary and Sexual Function After Radical Prostatectomy for Clinically Localized Prostate CancerJAMA, 2000
- ImpotenceJAMA, 1993